Hematologic DiseasesNCT00179946
HLA Matching - Unrelated Umbilical Cord Blood Transplantation
An observational study of Hematologic Diseases, run by Ann & Robert H Lurie Children's Hospital of Chicago at 1 site in United States.
Trial summary
The aim of this protocol is to clarify the role of HLA matching in unrelated umbilical cord blood (UCB) transplantation and to identify the level of HLA matching required assuring successful outcome of unrelated UCB transplantation. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Hematologic Diseases
- What is being tested?
- HLA typing
- Type of treatment
- Surgery or procedure
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2003to Apr 2006
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Pediatric Patients undergoing an unrelated umbilical cord blood transplantation.
Who cannot join
- Refusal to participate in study.
Trial locations and contacts
1 site in 1 country.
United States1 site
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
About this study
Official title: Impact of HLA Matching on Outcome in Pediatric Patients Undergoing Unrelated Umbilical Cord Blood Transplantation.
The aim of this protocol is to clarify the role of HLA matching in unrelated umbilical cord blood (UCB) transplantation and to identify the level of HLA matching required assuring successful outcome of unrelated UCB transplantation.
Read the detailed description
The aim of this protocol is to clarify the role of HLA matching in unrelated umbilical cord blood (UCB) transplantation and to identify the level of HLA matching required assuring successful outcome of unrelated UCB transplantation.
The study will answer the following questions:
- Is HLA matching beneficial to unrelated UCB transplantation?
- Which HLA loci, HLA-A, B, C, DRB1, or BQB1 is/are important to math, or alternatively to mismatch, to improve graft survival?
- Which HLA loci, HLA-A, B, C, DRB1, or BQB1 mismatches is/are "permissive mismatches" or well tolerated mismatches?
- What level of typing resolution (low, intermediate, or hgh) is required to perform patient/donor H:A matching?
By studying the cells and blood of donors and recipients, we may learn more about improving the tissue matching between unrelated donors and their recipients. Also, we hope to learn if an additional level of matching testing improves the results of the transplant treatment. Increasing knowledge about tissue matching could result in the improved long-term survival of cord blood transplant recipients.
- Conditions
- Hematologic Diseases
- Being tested
- HLA typing
- Medical subject headings
- Hematologic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HLA typingProcedure or surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2005 (estimated)
- Study startJun 2003
- Primary completionApr 2006
- Study completionApr 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematologic DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sonali Chadhury, MD, Principal investigator, Ann & Robert H Lurie Children's Hospital of Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00179946
- Sponsor's protocol ID
- BMT 0603 HLA
- Status last verified
- Jan 2025
- First submitted
- 12 Sep 2005
- Last updated
- 30 Jan 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of HLA Matching on Outcome in Pediatric Patients Undergoing Unrelated Umbilical Cord Blood Transplantation.
- ClinicalTrials.gov ID
- NCT00179946
- Acronym / sponsor ID
- BMT 0603 HLA
- Conditions
- Hematologic Diseases
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of ChicagoUniversity, hospital or other
- Study start
- Jun 2003
- Primary completion
- Apr 2006 (actual)
- Study completion
- Apr 2006 (actual)
- First posted
- 16 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this protocol is to clarify the role of HLA matching in unrelated umbilical cord blood (UCB) transplantation and to identify the level of HLA matching required assuring successful outcome of unrelated UCB transplantation.
Detailed description
The aim of this protocol is to clarify the role of HLA matching in unrelated umbilical cord blood (UCB) transplantation and to identify the level of HLA matching required assuring successful outcome of unrelated UCB transplantation.
The study will answer the following questions:
- Is HLA matching beneficial to unrelated UCB transplantation?
- Which HLA loci, HLA-A, B, C, DRB1, or BQB1 is/are important to math, or alternatively to mismatch, to improve graft survival?
- Which HLA loci, HLA-A, B, C, DRB1, or BQB1 mismatches is/are "permissive mismatches" or well tolerated mismatches?
- What level of typing resolution (low, intermediate, or hgh) is required to perform patient/donor H:A matching?
By studying the cells and blood of donors and recipients, we may learn more about improving the tissue matching between unrelated donors and their recipients. Also, we hope to learn if an additional level of matching testing improves the results of the transplant treatment. Increasing knowledge about tissue matching could result in the improved long-term survival of cord blood transplant recipients.
Study design
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Pediatric Patients undergoing an unrelated umbilical cord blood transplantation.
Key exclusion criteria (1 listed)
- Refusal to participate in study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HLA typing | Procedure or surgery | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2025.
Related trials for Hematologic Diseases
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Active, not recruitingPhase 3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Multiple Myeloma
RecruitingObservational study
A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma
Thrombotic Thrombocytopenic Purpura (TTP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sonali Chadhury, MD principal investigator
Ann & Robert H Lurie Children's Hospital of Chicago
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematologic Diseases, run by Ann & Robert H Lurie Children's Hospital of Chicago at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2025.